September 29, 2008 – The American College of Radiology's ACR Image Metrix completes one year of initiating projects for more than 12 drug and device companies and providing access to the latest CT, MR and nuclear medicine technology.
“We are very pleased with the success of our business model as a state-of-the-art core lab and our validated IT platform,” said Stephen King, ACR Image Metrix chief operating officer. “There is a significantly higher level of awareness for the value imaging expertise can add to clinical trials, as well as a growing understanding of the role ACR Image Metrix can play in expediting clinical trials.”
The ACR Image Metrix offers access to the American College of Radiology, a 32,000-member professional organization, and to the ACR Imaging Network (ACRIN), which has participated in clinical trials ranging from 65 to more than 50,000 subjects and involving more than 500 million images.
Morales said that Image Metrix will concentrate on CROs, pharmaceutical, biotech and medical device companies to provide services in Phase I-III clinical trials.
The state-of-the-art imaging core laboratories of Image Metrix provide clients access to the latest technologies, including CT, MRI/MRS, and PET/nuclear medicine. Recent trials have focused on the capacity of molecular and functional imaging to serve as biomarkers of the effectiveness of anticancer treatments.
“We’re ahead of where we wanted to be in our growth strategy,” Morales said. “We’re looking forward to accelerated growth in year two.”
For more information: www.acr-imagemetrix.net
April 20, 2026 
